MediWound (MDWD) EBITDA Margin (2014 - 2026)
MediWound (MDWD) posted EBITDA Margin of 305.89% for Q2 2026, up 35.16% on a QoQ basis from 471.73% in Q1 2026, and down 20575.0% year-over-year from N/an in Q2 2025.
Powered by 
Analysis
MediWound (MDWD) EBITDA Margin (2014 - 2026) Analysis & Trends
MediWound has reported EBITDA Margin for 13 years, with the latest figure at 305.89% in Q2 2026.
- On a quarterly basis, EBITDA Margin fell 20575.0% year-over-year to 305.89% in Q2 2026; TTM through Jun 2026 was 238.12%, a 14610.0% decrease from a year earlier, with the FY2025 full-year figure at 119.77%, down 4677.0% from the prior year.
- EBITDA Margin was 305.89% for Q2 2026 at MediWound, up from 471.73% in the prior quarter.
- The five-year high for EBITDA Margin was 29.47% in Q4 2022, with the low at 471.73% in Q1 2026.
- Average EBITDA Margin over 5 years is 121.05%, with a median of 84.16% recorded in 2023.
- The sharpest annual moves came in 2022 and 2026: EBITDA Margin soared 8150 bps in 2022, then tumbled 37011 bps in 2026.
- Over 5 years, EBITDA Margin stood at 29.47% in 2022, then slumped by 306 bps to 60.64% in 2023, then plunged by 37 bps to 83.29% in 2024, then tumbled by 316 bps to 346.28% in 2025, then gained by 12 bps to 305.89% in 2026.
- The last three EBITDA Margin figures came in at 305.89% (Q2 2026), 471.73% (Q1 2026), and 346.28% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -25,380.93% |
| 10 | MediWound | 156.09 Mn | 120.75 Mn | 337,000.00 | -305.89% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -305.89% |
| Mar 31, 2026 | -471.73% |
| Dec 31, 2025 | -346.28% |
| Sep 30, 2025 | -98.86% |
| Jun 30, 2025 | -100.14% |
| Mar 31, 2025 | -101.62% |
| Dec 31, 2024 | -83.29% |
| Sep 30, 2024 | -84.36% |
| Jun 30, 2024 | -88.56% |
| Mar 31, 2024 | -57.49% |
| Dec 31, 2023 | -60.64% |
| Sep 30, 2023 | -54.42% |
| Jun 30, 2023 | -83.95% |
| Mar 31, 2023 | -90.60% |
| Dec 31, 2022 | 29.47% |
| Sep 30, 2022 | -42.48% |
| Jun 30, 2022 | -78.71% |
| Mar 31, 2022 | -59.41% |
| Dec 31, 2021 | -52.03% |
| Sep 30, 2021 | -45.26% |